Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States

In the high-stakes environment of a hospital intensive care unit, doctors face a relentless adversary: bacteria that have learned to ignore the strongest antibiotics available. Among these, a specific germ known as Acinetobacter baumannii has become a particular nightmare when it develops resistance to a class of drugs called carbapenems. When this happens, the infection is labeled carbapenem-resistant, leaving clinicians with very few options to save a patient's life. One of the few remaining weapons in the medical arsenal is a drug called colistin, but it carries a heavy price. While it can kill the bacteria, it is also notorious for damaging the kidneys, often forcing patients into dialysis or causing other severe complications that extend their stay in the hospital and increase the risk of death. The medical community has long searched for a better alternative, one that could clear the infection without inflicting such heavy collateral damage on the patient's body.

Researchers recently turned their attention to a newer combination therapy called sulbactam-durlobactam to see if it could offer a better balance between saving lives and managing costs. To find the answer, they built a detailed computer model that simulated the journey of patients in critical care. This model drew its core data from a real-world clinical trial where patients were treated with either the new combination or the older colistin, both given alongside a standard antibiotic called imipenem-cilastatin. The simulation tracked not just whether the infection was cured, but also the survival rates and the frequency of acute kidney injury, a serious condition where the kidneys stop working properly. Because kidney failure is much more common in patients treated with colistin, the model carefully calculated the extra costs associated with managing this complication, weighing them against the higher price tag of the newer drug.

The results of this analysis painted a clear picture of the trade-offs involved. When looking at the total cost for a single patient, the newer treatment came in at $57,887, while the older colistin treatment cost $55,157. On the surface, the new drug appears more expensive. However, the story changes when looking at the outcome for the human life involved. Patients treated with sulbactam-durlobactam had a survival rate of 66 percent, compared to only 46 percent for those treated with colistin. This difference meant that for every patient treated with the new combination, there was a significant increase in the likelihood of survival. When the researchers calculated the extra cost required to save one additional life, they found it to be $14,097. This figure represents the extra money spent to gain that single life, a number that many health economists consider quite reasonable given the severity of the illness.

The study did not stop at a single calculation but tested how robust these findings were by changing various assumptions within the model. The results remained consistent even when the researchers adjusted for different rates of kidney injury or varying costs of other potential treatments. The analysis showed that the cost-effectiveness of the new drug was most sensitive to how many patients fully recovered from the infection and the specific costs of managing kidney failure. In some scenarios where the new drug performed even better, it actually became the cheaper option overall because it prevented so many costly kidney complications. Even in the less favorable scenarios, the cost to save an additional life ranged up to $69,758, which still falls within a range that many healthcare systems would accept for a life-saving intervention.

Ultimately, the study concludes that while the upfront price of sulbactam-durlobactam is higher, it offers a favorable value when the full picture is considered. By avoiding the frequent and expensive kidney damage associated with colistin, the newer treatment saves more lives at a cost that is justified by the outcome. The research suggests that for hospitals treating these difficult infections, switching to the newer combination could mean fewer patients dying and fewer suffering from kidney failure, making the higher initial drug cost a worthwhile investment in human life.